Copyright: ©Author(s) 2026.
World J Gastrointest Oncol. Nov 15, 2026; 18(11): 124022
Published online Nov 15, 2026. doi: 10.4251/wjgo.124022
Published online Nov 15, 2026. doi: 10.4251/wjgo.124022
Table 4 Grade ≥ 3 treatment-related adverse events in the two groups, n (%)
| Grade ≥ 3 AEs | Control group (n = 92) | Experimental group (n = 31) | P value |
| Myelosuppression | 3 (3.26) | 3 (9.68) | 0.341 |
| Nausea | 3 (3.26) | 0 (0.00) | 0.730 |
| Diarrhea | 3 (3.26) | 0 (0.00) | 0.730 |
| Fatigue | 1 (1.09) | 1 (3.23) | 1.000 |
| Proteinuria | 2 (2.17) | 0 (0.00) | 0.995 |
| Hypertension | 2 (2.17) | 0 (0.00) | 0.995 |
| Hepatic dysfunction | 3 (3.26) | 1 (3.23) | 1.000 |
| Thyroid dysfunction | 0 (0.00) | 1 (3.23) | 0.566 |
| Hand-foot syndrome | 0 (0.00) | 0 (0.00) | 1.000 |
- Citation: Zhang C, Wu SH, Jin L, Lu L, Li J, Jin S. Propensity score-based real-world study of immune checkpoint inhibitor combination therapy in microsatellite stable/proficient mismatch repair metastatic colorectal cancer. World J Gastrointest Oncol 2026; 18(11): 124022
- URL: https://www.wjgnet.com/1948-5204/full/v18/i11/124022.htm
- DOI: https://dx.doi.org/10.4251/wjgo.124022